Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Conditions: Diabetes
Interventions: carvedilol, metoprolol; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 45 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: REGN910-3, Intravitreal Aflibercept Injection (IAI); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 87
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more

Conditions: Advanced Solid Tumors
Interventions: IMC-18F1; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Detroit, Michigan • Cleveland, Ohio

Conditions: Pain
Interventions: Intravitreal injection site; Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: VEGF Trap-Eye 2.0mg, Sham; Biological · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more

Conditions: Obstructive Sleep Apnea of Adult
Interventions: Atorvastatin 10mg, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Postmenopausal Women
Interventions: nitrate rich beetroot juice, nitrate depleted beetroot juice; Drug
Lead sponsor: Penn State University; Other
Eligibility: Up to 70 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Coronary Artery Disease
Interventions: IPP, Placebo; Dietary Supplement · Other
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Smoking, Endothelial Dysfunction
Interventions: Electronic hookah vaping with nicotine, Electronic hookah vaping without nicotine; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 39 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Corneal Disease, Endothelial Corneal Dystrophy, Corneal Transplant Failure, Corneal Transplant Rejection
Interventions: Optical Coherence Tomography; Diagnostic Test
Lead sponsor: Nitin Vaswani; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Prediabetic State, Sedentary Lifestyle
Interventions: High Activity; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes, Retinopathy, Vascular Pathology
Interventions: Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatitis C
Interventions: Elbasvir/grazoprevir; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Endometrial Carcinoma
Interventions: Arsenic trioxide; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chronic Kidney Disease
Interventions: Flow-mediated dilation, single blood draw; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD, Macular Degeneration, Age-related, 10, Eye Diseases, Retinal Degeneration, Retinal Diseases
Interventions: X-82, Anti-VEGF, Placebo; Drug
Lead sponsor: Tyrogenex; Industry
Eligibility: 50 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 35
States / cities: Tucson, Arizona • Beverly Hills, California • Huntington Beach, California + 32 more

Conditions: Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Interventions: Combination Product: AURN001 + Y-27632, Placebo; Drug · Other
Lead sponsor: Aurion Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Mesa, Arizona • Little Rock, Arkansas • Fort Collins, Colorado + 9 more

Conditions: Menopause, Aging
Interventions: KUVAN, Placebo, Cetrotide, Climara, Placebo transdermal patch; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Coronary Artery Disease
Interventions: Clopidogrel, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Fluconazole 150 mg; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Norman, Oklahoma

Conditions: Adenocarcinoma of the Prostate
Interventions: Pazopanib, Placebo; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes Type 2
Interventions: Placebo, Aliskiren; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prediabetes, Obesity
Interventions: Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Comparison of Blood Pressure Medications on Metabolism

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy

Intravitreal Injection Site and Perceived Pain

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Endothelial Function in Obstructive Sleep Apnea

Postmenopausal Women and Their Endothelium

Effect of Ile-Pro-Pro (IPP) on Endothelial Function in Patients With Coronary Artery Disease

Electronic Hookah and Endothelial Cell Function

Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease

Physical Activity and Obesity

Microvascular Reactivity.

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

Trisenox® in Women With Metastatic Endometrial Cancer

Endothelial Microparticles: A Novel Marker of Vascular Dysfunction

X-82 to Treat Age-related Macular Degeneration

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

Investigation of the Athero-Protective Effects of Clopidogrel

Endothelial Derived Hyperpolarization Factor and Vascular Control

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes